A protein that triggers an imbalance of mucous and ciliated cells in patients with chronic lung disease could be a target for treatments to restore airways.
Genome-wide association study identifies two variants that may yield therapies for children with DMD.
Multiple steps lead to better control of disease, fewer emergency department visits and $5 million in savings.
Study also indicates early treatment may provide best outcomes.
A recent study suggests altered vagus nerve activity, creating resistance in the esophagus while swallowing.
Tests of NT-3 gene therapy on mouse models suggest potential to treat a host of muscle-wasting conditions.
Researchers find a related protein cloaking the virus has differences that could become treatment targets.
